Effects of Anabolic Steroid Use on muscle strength and weight gain in Critically Ill Non-Ventilated Patients. A Randomized Controlled Double Blind Study
Not Applicable
Recruiting
- Conditions
- Nutritional, Metabolic, Endocrine
- Registration Number
- PACTR202408913510687
- Lead Sponsor
- no sponsor
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Adult patients admitted to ICU for more than 2 weeks, who has
significant muscle weakness or weight loss more than 10% due to
ICU stay despite participating in physiotherapy program and
receiving full nutritional support.
Exclusion Criteria
• Intercurrent shock state
• Prostate or breast cancer.
• Active cardiac condition (EF<35%, or recent MI)
• Ongoing non-curable reason for catabolic state (active malignancy,
HIV).
• Pregnancy
• Nephrotic syndrome
• Elevated LFTs (ALT > 5-times normal ranges)
• Coagulopathy (INR >1.5 OR Platelets < 50)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This study aims to explore potential benefits and safety of administration of <br>anabolic steroid Decadurabolin to critically ill patients having muscle weakness.<br>Primary outcome: <br>to assess Quadriceps femoris muscle thickness (ultrasound guided) four times during time interval of the study
- Secondary Outcome Measures
Name Time Method • Length of ICU stay<br>• ICU mortality<br>• Improvement of muscle weakness<br>• Weight gain<br>• Diaphragmatic muscle thickness<br>